607 followers
【Olverembatinib (HQP1351)】 T315I変異陽性のCMLに対する臨床第I/II相試験結果 https://t.co/vAjRGKDlpm Phase 2 CP-CML+T315I https://t.co/mGDEy7M1yS Phase 2 AP-CML+T315I https://t.co/UKBeKkFOO2 Phase 2 CP-CML+T315I HQP vs BAT https://t.co/dU9rbpsmOY
【Olverembatinib (HQP1351)】 T315I変異陽性のCMLに対する臨床第I/II相試験結果 https://t.co/vAjRGKDlpm Phase 2 CP-CML+T315I https://t.co/mGDEy7M1yS Phase 2 AP-CML+T315I https://t.co/UKBeKkFOO2 Phase 2 CP-CML+T315I HQP vs BAT https://t.co/dU9rbpsmOY
This phase 1/2 study showed that olverembatinib is a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: https://t.co/yKbLzzGUiG https://t.co/9I51ExyBEp